ARMATA PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2020-11-12
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-09-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-06-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-03-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2019-09-30 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $0.00 10-Q · filed 2020-08-13 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-14 | |||
| 2018-12-31 | $0.00 10-Q · filed 2019-11-12 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $0.00 derived: sum of 2 quarters · filed 2017-05-15 | $0.00 derived: sum of 3 quarters · filed 2017-05-15 | $0.00 derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2017-05-15 | $0.00 derived: sum of 2 quarters · filed 2017-05-15 | $0.00 derived: sum of 3 quarters · filed 2017-05-15 | $0.00 10-Q · filed 2017-05-15 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 | $0.00 derived: sum of 2 quarters · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 | ||
| 2015-12-31 | $0.00 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |